Tech Company Financing Transactions

Dualitas Therapeutics Funding Round

Dualitas Therapeutics, based in San Francisco, secured $65 million in funding from Qiming Venture Partners USA, Versant Ventures and Alexandria Venture Investments.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

Undisclosed
San Francisco, CA Undisclosed
USA

Phone

Undisclosed

Website

www.dualitastx.com

Email Address

Not Recorded

Overview

Dualitas Therapeutics, Inc. is a biotechnology company pioneering next-generation bispecific antibody (BsAb) therapies for immunology and inflammation (I&I). Dualitas' portfolio, built from its DualScreen discovery engine, includes lead programs DTX-103 in allergic disease and DTX-102 in autoimmune disease, with numerous other discoveries based on cell-surface proximity biology and novel co-target pairing.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Rich Murray

        

Browse more venture capital transactions:

Prev: 9/16/2025: Clarity venture capital transaction
Next: 9/16/2025: MetalBear venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary